FLC
BIOSW

Fifth Lane Capital’s BioPlus Acquisition Corp. Warrants BIOSW Stock Holding History

Fifth Lane Capital’s Portfolio BIOSW Stock Details BIOSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-51,250
Closed -$12K – 458
2022
Q1 		$12K Buy
+51,250
New +$13.3K 0.01% 252

Other funds holding BIOSW

MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.1B AUM 64.05% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Fifth Lane Capital's BIOSW Position: Q2 2022 in Review

Fifth Lane Capital sold out of BioPlus Acquisition Corp. Warrants (BIOSW) in Q2 2022, closing a stake of 51,250 shares — an estimated $12K sold.

Fifth Lane Capital first reported a position in BIOSW in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 51 funds tracked by Wall St. Rank hold BIOSW as of Q2 2022.

  • Fifth Lane Capital reported no remaining BioPlus Acquisition Corp. Warrants position as of Q2 2022 after selling out during the quarter.
  • Fifth Lane Capital sold 51,250 BioPlus Acquisition Corp. Warrants shares in Q2 2022, an estimated $12K.
  • Fifth Lane Capital first reported a position in BioPlus Acquisition Corp. Warrants in Q1 2022 and held it in 1 quarter.
  • Fifth Lane Capital's BioPlus Acquisition Corp. Warrants position peaked at $12K in Q1 2022.
  • 51 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Warrants as of Q2 2022.

Based on Fifth Lane Capital's 13F filing for Q2 2022, filed 15 Aug 2022.